Brad Todd Undergoes Sinus Tumor Surgery at Johns Hopkins After 2020 Recurrence

Todd's account details the loss of olfactory function expected from this operation, contrasting with partial recovery after the prior surgery that allowed continued wine curation from Piemonte vineyards. The 2020 case originated from a routine Covid test that dislodged undetected tissue. Medical literature confirms ethmoid sinus malignancies occur in fewer than 500 U.S. cases annually, with treatment sequences typically involving resection followed by radiation.

The piece records concrete priority shifts post-2020 diagnosis: limiting advisory interventions to two iterations per client and attending nearly all children's high school athletic and performing events. These changes align with documented patterns in cancer survivor cohorts where mortality salience correlates with reallocation of time from professional to familial domains. No policy documents or institutional records are referenced.

Context from oncology follow-up data shows five-year survival for sinonasal malignancies ranges 40-60 percent depending on grade and margins. Todd notes the pandemic both precipitated and facilitated access to specialized otolaryngology care. Primary clinical records at Johns Hopkins would establish exact staging and margins, yet none are cited here.

Next steps include radiation with possible chemotherapy. Recovery timelines for olfaction loss post-ethmoid resection average six to twelve months when nerves remain intact; full restoration is rare after repeat procedures.